Skip to main content
Top
Published in: Tumor Biology 6/2012

01-12-2012 | Research Article

Expression of cGMP-dependent protein kinase, PKGIα, PKGIβ, and PKGII in malignant and benign breast tumors

Authors: Fatemeh Karami-Tehrani, Faranak Fallahian, Morteza Atri

Published in: Tumor Biology | Issue 6/2012

Login to get access

Abstract

Cyclic GMP-dependent protein kinases (PKG) constitute a small family of enzymes that are encoded by two genes. Two major forms of PKG have been identified in mammalian cells, PKG I and PKG II. In addition, there are two splice variants of PKG I, which are designated as Iα and Iβ. There are increasing evidences that PKG can play an important role in the inhibition of cell proliferation and induction of apoptosis. In our previous studies, the inhibitory effects of cGMP/PKG on the cell growth were indicated using breast cancer cell lines. Accordingly, the present study was designed to compare the expression levels of three PKG isoforms in normal, benign, and malignant breast tissues. The expression level of PKG isoforms was assayed using quantitative real-time RT-PCR. The correlation between relative expression of PKG isoforms and clinicopathological characteristics were also analyzed. Downregulation of PKG isoforms was observed in the malignant and benign tumors when compared to those of respective normal tissues. No significant correlation was found between PKGIα, PKGIβ, and PKGII expression and clinicopathological features. The present study is the first to evaluate the expression level of PKG isoforms PKGIα, PKGIβ, and PKGII in the malignant and benign breast tumors. Reduction in the PKG expression is an important evidence to support the antitumor activity of this enzyme in vivo.
Literature
1.
go back to reference Fiscus RR, Murad F. cGMP-dependent protein kinase activation in intact tissues. Methods Enzymol. 1988;159:150–9.CrossRef Fiscus RR, Murad F. cGMP-dependent protein kinase activation in intact tissues. Methods Enzymol. 1988;159:150–9.CrossRef
2.
go back to reference Hofmann F, Feil R, Kleppisch T, Schlossmann J. Function of cGMPdependent protein kinases as revealed by gene deletion. Physiol Rev. 2006;86:1–23.CrossRef Hofmann F, Feil R, Kleppisch T, Schlossmann J. Function of cGMPdependent protein kinases as revealed by gene deletion. Physiol Rev. 2006;86:1–23.CrossRef
3.
go back to reference Lincoln TM, Wu X, Sellak H, Dey N, Choi CS. Regulation of vascular smooth muscle cell phenotype by cyclic GMP and cyclic GMP dependent protein kinase. Front Biosci. 2006;11:356–67.CrossRef Lincoln TM, Wu X, Sellak H, Dey N, Choi CS. Regulation of vascular smooth muscle cell phenotype by cyclic GMP and cyclic GMP dependent protein kinase. Front Biosci. 2006;11:356–67.CrossRef
4.
go back to reference Orstavik S, Natarajan V, Tasken K, Jahnsen T, Sandberg M. Characterization of the human gene encoding the type I alpha and type I beta cGMP-dependent protein kinase (PRKG1). Genomics. 1997;42:311–8.CrossRef Orstavik S, Natarajan V, Tasken K, Jahnsen T, Sandberg M. Characterization of the human gene encoding the type I alpha and type I beta cGMP-dependent protein kinase (PRKG1). Genomics. 1997;42:311–8.CrossRef
5.
go back to reference Orstavik S, Solberg R, Tasken K, Nordahl M, Altherr MR, Hansson V, Jahnsen T, Sandberg M. Molecular cloning, cDNA structure and chromosomal localization of the human type cGMP-dependent protein kinase. Biochem Biophys res Commun. 1996;220:759–65.CrossRef Orstavik S, Solberg R, Tasken K, Nordahl M, Altherr MR, Hansson V, Jahnsen T, Sandberg M. Molecular cloning, cDNA structure and chromosomal localization of the human type cGMP-dependent protein kinase. Biochem Biophys res Commun. 1996;220:759–65.CrossRef
6.
go back to reference Gamm DM, Francis SH, Angelotti TP, Uhler MD. The type isoform of cGMP-dependent protein kinase is dimeric and possesses regulatory and catalytic properties distinct from the type isoforms. J Biol chem. 1995;270:27380–8.CrossRef Gamm DM, Francis SH, Angelotti TP, Uhler MD. The type isoform of cGMP-dependent protein kinase is dimeric and possesses regulatory and catalytic properties distinct from the type isoforms. J Biol chem. 1995;270:27380–8.CrossRef
7.
go back to reference Lohmann SM, Vaandrager AB, Smolenski A, Walter U, De Jonge HR. Distinct and specific functions of cGMP-dependent protein kinases. Trends Biochem Sci. 1997;22:307–12.CrossRef Lohmann SM, Vaandrager AB, Smolenski A, Walter U, De Jonge HR. Distinct and specific functions of cGMP-dependent protein kinases. Trends Biochem Sci. 1997;22:307–12.CrossRef
8.
go back to reference Lincoln TM, Dey N, Sellak H. Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. J Appl Physiol. 2001;91:1421–30.CrossRef Lincoln TM, Dey N, Sellak H. Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. J Appl Physiol. 2001;91:1421–30.CrossRef
9.
go back to reference Lohmann SM, Fischmeister R, Walter U. Signal transduction by cGMP in heart. Basic Res Cardiol. 1991;86:503–14.CrossRef Lohmann SM, Fischmeister R, Walter U. Signal transduction by cGMP in heart. Basic Res Cardiol. 1991;86:503–14.CrossRef
10.
go back to reference Uhler MD. Cloning and expression of a novel cyclic GMP-dependent protein kinase from mouse brain. J Biol Chem. 1993;268:13586–91.CrossRef Uhler MD. Cloning and expression of a novel cyclic GMP-dependent protein kinase from mouse brain. J Biol Chem. 1993;268:13586–91.CrossRef
11.
go back to reference Shimojo T, Hiroe M, Ishiyama S, Ito H, Nishikawa T, Marumo F. Nitric oxide induces apoptotic death of cardiomyocytes via a cyclic-GMP-dependent pathway. Exp Cell Res. 1999;247:38–47.CrossRef Shimojo T, Hiroe M, Ishiyama S, Ito H, Nishikawa T, Marumo F. Nitric oxide induces apoptotic death of cardiomyocytes via a cyclic-GMP-dependent pathway. Exp Cell Res. 1999;247:38–47.CrossRef
12.
go back to reference Loweth AC, Williams GT, Scarpello JNB, Morgan NG. Evidence for the involvement of cGMP and protein kinase G in nitric oxide-induced apoptosis in the pancreatic B-cell line, HIT-T15. FEBS Lett. 1997;400:285–8.CrossRef Loweth AC, Williams GT, Scarpello JNB, Morgan NG. Evidence for the involvement of cGMP and protein kinase G in nitric oxide-induced apoptosis in the pancreatic B-cell line, HIT-T15. FEBS Lett. 1997;400:285–8.CrossRef
13.
go back to reference Kaminski A, Gao H, Morgan NG. Involvement of the cGMP signalling pathway in the regulation of viability in insulin-secreting BRIN-BD11 cells. FEBS Lett. 2004;559:118–24.CrossRef Kaminski A, Gao H, Morgan NG. Involvement of the cGMP signalling pathway in the regulation of viability in insulin-secreting BRIN-BD11 cells. FEBS Lett. 2004;559:118–24.CrossRef
14.
go back to reference Cook AL, Haynes JM. Protein kinase G II-mediated proliferative effects in human cultured prostatic stromal cells. Cell Signal. 2004;16:253–61.CrossRef Cook AL, Haynes JM. Protein kinase G II-mediated proliferative effects in human cultured prostatic stromal cells. Cell Signal. 2004;16:253–61.CrossRef
15.
go back to reference Chiche JD, Schlutsmeyer SM, Bloch DB, De la Monte SM, Roberts JD. Adenovirus-mediated gene transfer of cGMP-dependent protein kinase increases the sensitivity of cultured vascular smooth muscle cells to the antiproliferative and pro-apoptotic effects of nitric oxide/cGMP. J Biol Chem. 1998;273:34263–71.CrossRef Chiche JD, Schlutsmeyer SM, Bloch DB, De la Monte SM, Roberts JD. Adenovirus-mediated gene transfer of cGMP-dependent protein kinase increases the sensitivity of cultured vascular smooth muscle cells to the antiproliferative and pro-apoptotic effects of nitric oxide/cGMP. J Biol Chem. 1998;273:34263–71.CrossRef
16.
go back to reference Deguchi A, Thompson WJ, Weinstein IB. Activation of protein kinase G is sufficient to induce apoptosis and inhibit cell migration in colon cancer cells. Cancer Res. 2004;64:3966–73.CrossRef Deguchi A, Thompson WJ, Weinstein IB. Activation of protein kinase G is sufficient to induce apoptosis and inhibit cell migration in colon cancer cells. Cancer Res. 2004;64:3966–73.CrossRef
17.
go back to reference Browning DD. cGMP-dependent protein kinases as potential targets for colon cancer prevention and treatment. Future Med Chem. 2010;2:65–80.CrossRef Browning DD. cGMP-dependent protein kinases as potential targets for colon cancer prevention and treatment. Future Med Chem. 2010;2:65–80.CrossRef
18.
go back to reference Browning DD. Protein kinase G as a therapeutic target for the treatment of metastatic colorectal cancer. Expert Opin Biol Ther. 2008;8:1–10.CrossRef Browning DD. Protein kinase G as a therapeutic target for the treatment of metastatic colorectal cancer. Expert Opin Biol Ther. 2008;8:1–10.CrossRef
19.
go back to reference Fallahian F, Karami-Tehrani F, Salami S, Aghaei M. Cyclic GMP induced apoptosis via protein kinase G in oestrogen receptor-positive and -negative breast cancer cell lines. FEBS J. 2011;278:3360–9.CrossRef Fallahian F, Karami-Tehrani F, Salami S, Aghaei M. Cyclic GMP induced apoptosis via protein kinase G in oestrogen receptor-positive and -negative breast cancer cell lines. FEBS J. 2011;278:3360–9.CrossRef
20.
go back to reference Fallahian F, Karami-Tehrani F, Salami S. Induction of apoptosis by type Iβ protein kinase G in the human breast cancer cell lines MCF-7 and MDA-MB-468. Cell Biochem Func. 2012;30:183–90.CrossRef Fallahian F, Karami-Tehrani F, Salami S. Induction of apoptosis by type Iβ protein kinase G in the human breast cancer cell lines MCF-7 and MDA-MB-468. Cell Biochem Func. 2012;30:183–90.CrossRef
21.
go back to reference Soh JW, Mao Y, Kim MG, Pamukcu R, Li H, Piazza GA, Thompson WJ, Weinstein IB. Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1. Clin Cancer Res. 2000;6:4136–41.PubMed Soh JW, Mao Y, Kim MG, Pamukcu R, Li H, Piazza GA, Thompson WJ, Weinstein IB. Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1. Clin Cancer Res. 2000;6:4136–41.PubMed
22.
go back to reference Soh JW, Mao Y, Liu L, Thompson WJ, Pamukcu R, Weinstein IB. Protein kinase G activates the JNK1 pathway via phosphorylation of MEKK1. J Biol Chem. 2001;276:16406–10.CrossRef Soh JW, Mao Y, Liu L, Thompson WJ, Pamukcu R, Weinstein IB. Protein kinase G activates the JNK1 pathway via phosphorylation of MEKK1. J Biol Chem. 2001;276:16406–10.CrossRef
23.
go back to reference Thompson WJ, Piazza GA, Li H, Liu L, Fetter J, Zhu B, Sperl G, Ahnen D, Pamukcu R. Exisulind induction of apoptosis involves guanosine 3 ′,5 ′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000;60:3338–42.PubMed Thompson WJ, Piazza GA, Li H, Liu L, Fetter J, Zhu B, Sperl G, Ahnen D, Pamukcu R. Exisulind induction of apoptosis involves guanosine 3 ′,5 ′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000;60:3338–42.PubMed
24.
go back to reference Lin G, Chow S, Lin J, Wang G, Lue TF, Lin CS. Effect of cell passage and density on protein kinase G expression and activation in vascular smooth muscle cells. J Cell Biochem. 2004;92:104–12.CrossRef Lin G, Chow S, Lin J, Wang G, Lue TF, Lin CS. Effect of cell passage and density on protein kinase G expression and activation in vascular smooth muscle cells. J Cell Biochem. 2004;92:104–12.CrossRef
25.
go back to reference Cornwell TL, Lincoln TM. Regulation of intracellular Ca2+ levels in cultured vascular smooth muscle cells. Reduction of Ca2+ by atriopeptin and 8-bromo-cyclic GMP is mediated by cyclic GMP-dependent protein kinase. J Biol Chem. 1989;264:1146–55.CrossRef Cornwell TL, Lincoln TM. Regulation of intracellular Ca2+ levels in cultured vascular smooth muscle cells. Reduction of Ca2+ by atriopeptin and 8-bromo-cyclic GMP is mediated by cyclic GMP-dependent protein kinase. J Biol Chem. 1989;264:1146–55.CrossRef
26.
go back to reference Vaandrager AB, Tilly BC, Smolenski A, Schneider-Rasp S, Bot AG, Edixhoven M, Scholte BJ, Jarchau T, Walter U, Lohmann SM, Poller WC, de Jonge HR. cGMP stimulation of cystic fibrosis transmembrane conductance regulator Cl– channels co-expressed with cGMP-dependent protein kinase type II but not type Iβ. J Biol Chem. 1997;272:4195–200.CrossRef Vaandrager AB, Tilly BC, Smolenski A, Schneider-Rasp S, Bot AG, Edixhoven M, Scholte BJ, Jarchau T, Walter U, Lohmann SM, Poller WC, de Jonge HR. cGMP stimulation of cystic fibrosis transmembrane conductance regulator Cl– channels co-expressed with cGMP-dependent protein kinase type II but not type Iβ. J Biol Chem. 1997;272:4195–200.CrossRef
27.
go back to reference Hou Y, Gupta N, Schoenlein P, Wong E, Martindale R, Ganapathy V, Browning DD. An anti-tumor role for cGMP-dependent protein kinase. Cancer Lett. 2006;240:60–8.CrossRef Hou Y, Gupta N, Schoenlein P, Wong E, Martindale R, Ganapathy V, Browning DD. An anti-tumor role for cGMP-dependent protein kinase. Cancer Lett. 2006;240:60–8.CrossRef
28.
go back to reference Leung EL, Wong JC, Johlfs MG, Tsang BK, Fiscus RR. Protein kinase G type Ialpha activity in human ovarian cancer cells significantly contributes to enhanced Src activation and DNA synthesis/cell proliferation. Mol Cancer Res. 2010;8:578–91.CrossRef Leung EL, Wong JC, Johlfs MG, Tsang BK, Fiscus RR. Protein kinase G type Ialpha activity in human ovarian cancer cells significantly contributes to enhanced Src activation and DNA synthesis/cell proliferation. Mol Cancer Res. 2010;8:578–91.CrossRef
29.
go back to reference Tinsley HN, Gary BD, Keeton AB, Zhang W, Abadi AH, Reynolds RC, Piazza GA. Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol Cancer Ther. 2009;8:3331–40.CrossRef Tinsley HN, Gary BD, Keeton AB, Zhang W, Abadi AH, Reynolds RC, Piazza GA. Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol Cancer Ther. 2009;8:3331–40.CrossRef
30.
go back to reference Deguchi A, Das KK, Xing SW, Oehlen B, Weinstein IB (2005) Down-regulation of the cGMP/PKG pathway in primary human colon cancers and cancer cell lines. Experimental and Molecular Therapeutics 20 (Abstract) Deguchi A, Das KK, Xing SW, Oehlen B, Weinstein IB (2005) Down-regulation of the cGMP/PKG pathway in primary human colon cancers and cancer cell lines. Experimental and Molecular Therapeutics 20 (Abstract)
31.
go back to reference Kwon IK, Schoenlein PV, Delk J, Liu K, Thangaraju M, Dulin NO, Ganapathy V, Berger FG, Browning DD. Expression of cyclic guanosine monophosphate-dependent protein kinase in metastatic colon carcinoma cells blocks tumor angiogenesis. Cancer. 2008;112:1462–70.CrossRef Kwon IK, Schoenlein PV, Delk J, Liu K, Thangaraju M, Dulin NO, Ganapathy V, Berger FG, Browning DD. Expression of cyclic guanosine monophosphate-dependent protein kinase in metastatic colon carcinoma cells blocks tumor angiogenesis. Cancer. 2008;112:1462–70.CrossRef
32.
go back to reference Tinsley HN, Gary BD, Keeton AB, Lu W, Li Y, Piazza GA. Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/β-catenin-mediated transcription in human breast tumor cells. Cancer Prev Res (Phila). 2011;4:1275–84.CrossRef Tinsley HN, Gary BD, Keeton AB, Lu W, Li Y, Piazza GA. Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/β-catenin-mediated transcription in human breast tumor cells. Cancer Prev Res (Phila). 2011;4:1275–84.CrossRef
33.
go back to reference Lustig B, Behrens J. The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol. 2003;129:199–221.CrossRef Lustig B, Behrens J. The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol. 2003;129:199–221.CrossRef
Metadata
Title
Expression of cGMP-dependent protein kinase, PKGIα, PKGIβ, and PKGII in malignant and benign breast tumors
Authors
Fatemeh Karami-Tehrani
Faranak Fallahian
Morteza Atri
Publication date
01-12-2012
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2012
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0453-9

Other articles of this Issue 6/2012

Tumor Biology 6/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine